G Targher1, I Pichiri, G Zoppini, M Trombetta, E Bonora. 1. Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy. giovanni.targher@univr.it
Abstract
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of cardiovascular disease (CVD) in both non-diabetic and Type 2 diabetic individuals. We sought to examine whether NAFLD is associated with prevalent CVD in patients with Type 1 diabetes. SUBJECTS AND METHODS: We studied 343 (156 men; mean age ~45 yr) consecutive Type 1 diabetic patients with and without NAFLD, which was diagnosed by ultrasonography. The presence of CVD was diagnosed by patient history, chart review, electrocardiogram, and echo-Doppler scanning of carotid and lower limb arteries. RESULTS: Compared with those without steatosis, patients with ultrasound-diagnosed NAFLD (no.=182) had a remarkably greater age- and sex-adjusted prevalence of coronary (15.4 vs 1.2%, p<0.0001), cerebrovascular (41.7 vs 9.3%, p<0.0001) and peripheral (29.7 vs 6.2%, p<0.0001) vascular disease. A multivariable logistic regression analysis revealed that NAFLD was associated with an ~8-fold higher odds of CVD (composite endpoint), independently of age, sex, body mass index, family history of CVD, smoking status, physical activity, alcohol consumption, diabetes duration, glycated hemoglobin, systolic blood pressure, plasma lipids, estimated glomerular filtration rate, albuminuria, and use of anti-hypertensive, lipid-lowering and anti-platelet medications (adjusted odds ratio 7.6, 95% confidence intervals 3.6-24.0, p<0.001). CONCLUSIONS: Our results demonstrate that NAFLD is associated with an increased prevalence of asymptomatic/symptomatic CVD in patients with Type 1 diabetes, independently of several established risk factors, including the components of metabolic syndrome.
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of cardiovascular disease (CVD) in both non-diabetic and Type 2 diabetic individuals. We sought to examine whether NAFLD is associated with prevalent CVD in patients with Type 1 diabetes. SUBJECTS AND METHODS: We studied 343 (156 men; mean age ~45 yr) consecutive Type 1 diabeticpatients with and without NAFLD, which was diagnosed by ultrasonography. The presence of CVD was diagnosed by patient history, chart review, electrocardiogram, and echo-Doppler scanning of carotid and lower limb arteries. RESULTS: Compared with those without steatosis, patients with ultrasound-diagnosed NAFLD (no.=182) had a remarkably greater age- and sex-adjusted prevalence of coronary (15.4 vs 1.2%, p<0.0001), cerebrovascular (41.7 vs 9.3%, p<0.0001) and peripheral (29.7 vs 6.2%, p<0.0001) vascular disease. A multivariable logistic regression analysis revealed that NAFLD was associated with an ~8-fold higher odds of CVD (composite endpoint), independently of age, sex, body mass index, family history of CVD, smoking status, physical activity, alcohol consumption, diabetes duration, glycated hemoglobin, systolic blood pressure, plasma lipids, estimated glomerular filtration rate, albuminuria, and use of anti-hypertensive, lipid-lowering and anti-platelet medications (adjusted odds ratio 7.6, 95% confidence intervals 3.6-24.0, p<0.001). CONCLUSIONS: Our results demonstrate that NAFLD is associated with an increased prevalence of asymptomatic/symptomatic CVD in patients with Type 1 diabetes, independently of several established risk factors, including the components of metabolic syndrome.
Authors: Dario Greco; Anna Kotronen; Jukka Westerbacka; Oscar Puig; Perttu Arkkila; Tuula Kiviluoto; Saara Laitinen; Maria Kolak; Rachel M Fisher; Anders Hamsten; Petri Auvinen; Hannele Yki-Järvinen Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-04-03 Impact factor: 4.052
Authors: Faidon Magkos; Elisa Fabbrini; B Selma Mohammed; Bruce W Patterson; Samuel Klein Journal: Obesity (Silver Spring) Date: 2010-04-15 Impact factor: 5.002
Authors: Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal Journal: Hepatology Date: 2003-06 Impact factor: 17.425
Authors: Cynthia J Girman; Thomas Rhodes; Michele Mercuri; Kalevi Pyörälä; John Kjekshus; Terje R Pedersen; Polly A Beere; Antonio M Gotto; Michael Clearfield Journal: Am J Cardiol Date: 2004-01-15 Impact factor: 2.778
Authors: Jukka Westerbacka; Maria Kolak; Tuula Kiviluoto; Perttu Arkkila; Jukka Sirén; Anders Hamsten; Rachel M Fisher; Hannele Yki-Järvinen Journal: Diabetes Date: 2007-08-17 Impact factor: 9.461
Authors: Julia Jäger; Vera Greiner; Daniela Strzoda; Oksana Seibert; Katharina Niopek; Tjeerd P Sijmonsma; Michaela Schäfer; Allan Jones; Roldan De Guia; Marc Martignoni; Geesje M Dallinga-Thie; Mauricio B Diaz; Thomas G Hofmann; Stephan Herzig Journal: Mol Metab Date: 2014-01-08 Impact factor: 7.422